- Why Cryoport
- Who We Serve
- About Us
- News & Events
- Investor Relations
- Contact Us
Cryoport is excited to announce we have expanded our global supply chain network and services through the agreement to acquire of CRYOPDP, a leading global provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical and cell and gene therapy markets, headquartered in Paris, France. Upon completion of the acquisition, CRYOPDP will provide significant complementary synergies with Cryoport Systems, with very limited overlap in capabilities and infrastructure, from a geographic as well as service and product support standpoint.
This acquisition will build upon Cryoport’s overall mission in providing reliable and comprehensive temperature-controlled logistics solutions for the life sciences industry. CRYOPDP shares the same value propositions and commitment as Cryoport – high standards, quality-focused, innovative, and complete dedication to the life science industry. Together, we will be able to provide unparalleled support in delivering valuable materials to researchers, manufacturers, biopharma partners, and their patients worldwide.
With over 220 dedicated employees located in 22 global facilities, CRYOPDP will immediately enhance and broaden Cryoport’s geographic footprint and infrastructure within Europe, India, and the Asia Pacific regions. Additionally, the acquisition will provide immediate, tangible synergies to our mutual client base in support of their storage, packaging, and distribution needs.
CRYOPDP covers a significant portion of the healthcare temperature-controlled supply chain including packaging, pick-pack kit preparation, express services, and specialty courier support. Cryoport’s current and future clients will be able to benefit from these comprehensive solutions.
In conjunction with the Cryoportal® Logistics Management Platform, CRYOPDP’s complementing UnITy ITSM platform will create an integrated global logistics solution that guarantees full visibility, control, and integrity of chain of custody and chain of condition. These integrated platforms provide operational excellence across all temperature ranges and falls into Cryoport’s Chain of Compliance®, which is an important part of our continuous effort in de-risking cell and gene therapy distribution.
At Cryoport, we understand the complexity of the life sciences supply chain. With the acquisition of CRYOPDP, we will be able to provide global, market-leading support to the most complex and highest value life sciences product supply chains.
Please “stay tuned” for more details about CRYOPDP and how you will be able to benefit from the expanded support services. For immediate questions and inquiries, please fill out the form below.
To read this full story, check out our Press Release: Cryoport Expands Global Supply Chain Platform by Signing Agreement to Acquire CRYOPDP